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Ultraviolet light exposure is the major risk factor for
the development of squamous cell carcinoma in
Caucasians. Mutations in the tumor suppressor gene
p53 have been identi®ed in both squamous cell carci-
nomas and basal cell carcinomas. The human homo-
log of the Drosophila patched gene, has been shown to
be mutated in sporadic basal cell carcinomas; how-
ever, mutations in the patched gene have not been
found in squamous cell carcinoma. In this study, we
screened a total of 20 squamous cell carcinoma sam-
ples for mutations in the patched gene. Using poly-
merase chain reaction±single strand conformation
polymorphism as an initial screening method, we
identi®ed one non-sense mutation, two mis-sense
mutations and three silent mutations in ®ve squa-
mous cell carcinoma samples. In one squamous cell
carcinoma sample, we identi®ed a tandem GG®AA
transitional change at nucleotide 3152 in exon 18 of
the patched gene that resulted in a premature stop
codon at codon 1051. The three squamous cell carci-
noma samples containing non-sense and mis-sense
mutations were isolated from individuals with histor-
ies of multiple basal cell carcinoma. Sequence analy-
sis of the p53 gene in these ®ve squamous cell
carcinoma samples identi®ed one CC®TT and three
C®T ultraviolet-speci®c nucleotide changes. Our
study provides evidence that the patched gene is
mutated in squamous cell carcinoma from individ-
uals with a history of multiple basal cell carcinoma.
The identi®cation of ultraviolet-speci®c nucleotide
changes in both tumor suppressor genes supports the
notion that ultraviolet exposure plays an important
part in the development of squamous cell carcinoma.
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C
utaneous squamous cell carcinoma (SCC) is the
second most common skin cancer and occurs most
frequently in Caucasians (Johnson et al, 1992; Preston
and Stern, 1992). Sunlight exposure has been linked
directly to the development of SCC in individuals
with fair skin, as most SCC occur on heavily sun-exposed sites
(Johnson et al, 1992; Marks, 1996). Other risk factors for the
development of SCC include immunosuppression, arsenic ex-
posure, ionizing radiation, and chronically injured or diseased skin
(Cohen et al, 1987; Bernstein et al, 1996; Mittelbronn et al, 1998;
Wong et al, 1998). In contrast to basal cell carcinoma (BCC), which
has no precursor lesions, SCC can arise from actinic keratoses and
Bowen's disease (carcinoma in situ) (Brash and Ponten, 1998).
Germline mutations in the human homolog of the Drosophila
patched gene, PTCH, were demonstrated in individuals with nevoid
BCC syndrome (Hahn et al, 1996; Johnson et al, 1996).
Subsequently, somatic mutations in the PTCH gene were identi-
®ed in 20±30% of the sporadic BCC studied (Chidambaram et al,
1996; Gailani et al, 1996; Hahn et al, 1996; Johnson et al, 1996;
Unden et al, 1996; Wolter et al, 1997; Aszterbaum et al, 1998).
Somatic mutations in the PTCH gene were also identi®ed in
tumors derived from brain, breast, bladder, and esophageal tissues
with an average frequency of 3±10% of the samples studied (Xie et
al, 1997; Wolter et al, 1997; Maesawa et al, 1998; McGarvey et al,
1998).
Loss of heterozygosity on chromosome 9q22.3, where the
PTCH gene is located, has been shown in SCC (Ahmadian et al,
1998; Eklund et al, 1998); however, one study of 14 SCC samples
failed to reveal any PTCH mutations (Eklund et al, 1998). Increased
incidence of SCC has been observed in ultraviolet (UV) -irradiated
PTCH heterozygous knockout mice (Aszterbaum et al, 1999).
Interestingly, these SCC retained their PTCH wild-type allele. In
this study, we screened a total of 20 SCC samples for mutations in
the PTCH gene. Polymerase chain reaction±single strand con-
formation polymorphism (PCR±SSCP) was used as an initial
screening method, and PCR products showing SSCP variants were
then sequenced to con®rm the mutation.
MATERIALS AND METHODS
DNA extraction Paraf®n sections containing tumor tissue were placed
into 1.5 ml microcentrifuge tubes and washed in xylene three times for
30 min each. The sections were then digested in a buffer with proteinase
K (provided in the QiAamp tissue kit, Qiagen, Valencia, CA) at 55°C
overnight. The tumor genomic DNA was then extracted following the
instructions and using columns provided by the QiAamp Tissue Kit from
Qiagen.
SSCP analysis SSCP±PCR reaction mixtures containing 25 ng of
each primer, 22.5 ml of Platinum PCR supermix (Life Technology,
Rockville, MD) and 0.5 ml of [33P]deoxycytidine triphosphate (NEN,
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Boston, MA) were subjected to 30 cycles of PCR ampli®cation. After
thermal cycling, 1 ml of PCR product was added to 10 ml of stop
solution (95% formamide; 10 mM NaOH, 0.25% bromophenol blue, and
0.25% xylene cyanol). The mixtures were heated to 94°C for 3 min and
placed on ice immediately. Three microliters of the denatured mixtures
were loaded on to a 0.5 3 Mutation Detection Enhancement gel
solution (FMC Bioproducts, Rockland, ME) with 10% glycerol and run
at 10 W for 20 h at room temperature. PCR products with SSCP
variants were sequenced using a BigDye terminator cycle sequencing kit
(ABI, Columbia, MD) and were then run on an Applied Biosystem 310
automated sequencing system (Applied Biosystems, Foster City, CA).
Mutation screening for the PTCH gene A set of 20 pairs of primers
¯anking exon 3 to exon 23 of the PTCH gene, as previously described
(Hahn et al, 1996; Xie et al, 1997), was used to amplify tumor genomic
DNA. These PCR amplicons were then subjected to an SSCP±PCR
reaction with the nested primers. PCR products containing SSCP
variants were then sequenced and analyzed on an Applied Biosystems
model 310 DNA sequencer. Mutations were con®rmed with repeated
PCR and sequence reactions starting from genomic DNA.
Mutation screening for the p53 gene Each tumor sample was
screened for mutations in exon 4 to exon 8 of the p53 gene by direct
sequencing analysis. Genomic DNA from each tumor was subjected to
PCR ampli®cation with primers ¯anking each exon of the p53 gene
(Table I). The resulting amplicons were then sequenced and analyzed
on an Applied Biosystems model 310 DNA sequencer. Each mutation
was con®rmed by new PCR and sequence reactions starting from
genomic DNA.
RESULTS AND DISSCUSSION
The hematoxylin and eosin sections from each of the 20 tumors
were reviewed and the diagnosis of SCC was con®rmed. The
paraf®n sections used in this study contain over 50% of tumor
tissues. Three SCC samples, S006, DS17, and Ap85, were isolated
from individuals with histories of multiple BCC. These three
individuals were over 70 and the multiple BCC were caused by
accumulation of UV damage, and do not represent familial cases.
Genomic DNA isolated from each SCC sample was ampli®ed
with primers ¯anking the coding sequences of the PTCH gene.
PCR±SSCP analysis was performed and six SSCP variants were
detected in DNA from ®ve SCC samples. Sequence analysis of
these SSCP variants revealed one tandem nucleotide change and
®ve single nucleotide changes. A tandem GG®AA transitional
change at nucleotides 3152±3153 in exon 18 of the PTCH gene
was detected in SCC sample S006, resulting in a premature stop
codon at codon 1051 (see Fig 1). S006 is a poorly differentiated
SCC with an abundant mitosis that was isolated from the lower
back of a 77 y old Caucasian male. The wild-type allele of the
PTCH gene was lost in this poorly differentiated tumor. Sequence
Table I. Primers for the the p53 gene
Exon 4 AATGGATGATTTGATGCTGTCCC
CTCAGGGCAACTGACCGTGC
Exon 5 TTCCTCTTCCTGCAGTACTC
GCCCCAGCTGCTCACCATCG
Exon 6 CTGATTGCTCTTAGGTCTGG
AGTTGCAAACCAGACCTCAG
Exon 7 GTGTTGTCTCCTAGGTTGGC
AAGTGGCTCCTGACCTGGAG
Exon 8 AGTGGTAATCTACTGGGACG
ATTCTCCATCCAGTGGTTTC
Table II. PTCH and p53 mutations
No. Sex Age Site PTCH p53
Ex Nucleotide Effect Ex Nucelotide Effect
S006 M 77 Left lower back 18 3152-3GG®AA W1051X
DS17 M 73 Left anterial shoulder 15 2485G®A V828M
Ap85 M 78 Right forehead 15 2334G®A T778T 6 560±1,560CC®TT splice site mutation and G187L
22 3742G®A E1242K
S060 M 58 Left cheek 12 1725C®T L575L 4
5
6
238C®T
535C®T
586C®T
P80S
H179Y
R196X
AP128 M 61 Left nasal sidewall 19 3240C®T A1080A
Figure 1. Identi®cation of a nonsense
mutation in the PTCH gene from SCC
sample. SSCP analysis showed a shifted band in
PCR product encoding exon 18 of the PTCH
gene, compared with the normal control DNA
samples isolated from individuals with wild-type
PTCH sequences. Sequence analysis of this PCR
product containing shifted band revealed a
GG®AA tandem nucleotide change at nucleotide
3152 and 3153, which resulted in a premature
stop codon at 1051.
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analysis of DNA from the adjacent normal skin did not reveal the
same PTCH mutation.
In SCC samples, DS17 and Ap85, we detected two single
nucleotide changes, resulting in mis-sense mutations in exon 15 and
exon 22, respectively (see Table II). These tumors were isolated
from two Caucasian males in their seventies with a history of
multiple BCC. In addition, we detected three single nucleotide
changes in coding sequences of the PTCH gene that did not result
in any amino acid substitutions (see Table II). The wild-type
alleles of the PTCH gene were present in SCC samples containing
these ®ve single nucleotide changes. The adjacent normal tissues in
three SCC samples (Ap128, Ap85, and S060) showed no
nucleotide changes. We were not able to obtain the corresponding
normal tissue for tumor DS 17. All ®ve single nucleotide changes
occurred on bases that are conserved and not detected in 40 normal
control alleles, suggesting that they were not sequence polymorph-
isms.
Most PTCH mutations identi®ed in nevoid BCC syndrome
individuals and sporadic BCC resulted in truncated PTCH proteins
(Wicking et al, 1997). Of the three PTCH mutations identi®ed in
the SCC samples from this study, only one was a tandem nucleotide
change, resulting in a truncated PTCH protein. The other two
were single nucleotide changes that led to mis-sense mutations. All
®ve nucleotide changes detected in this study occurred on bases
that are conserved, and the functional signi®cance of these
nucleotide changes is unclear.
Two of the ®ve SCC samples with nucleotide changes in the
PTCH gene, also contained UV speci®c changes in the p53 gene.
Over 50% of SCC examined to date have mutations in the p53
gene, most of them UV speci®c mutations (Brash et al, 1991; Kubo
et al, 1994). The prevalence of UV-speci®c p53 mutations in SCC
is higher than in BCC, suggesting that UV irradiation is more
directly linked to the development of SCC than BCC. A study
using PTCH heterozygous mice showed a direct UV effect in the
development of SCC in these animals (Aszterbaum et al, 1999). The
six nucleotide changes detected in our SCC samples, two C®T,
one GG®AA, and three G®A nucleotide changes in the PTCH
gene, are known to be UV speci®c. Furthermore, three SCC
samples containing PTCH mutations were isolated from individuals
who are over the age of 70 and with sun-damaged skin (evident by
a history of multiple BCC). Our data con®rmed the observation
that UV exposure plays an important part in the development of
SCC.
In conclusion, our study provides evidence that the PTCH gene
is mutated in a subset of SCC from individuals with a history of
multiple BCC. We identi®ed PTCH mutations in 15% (three of
20) of SCC samples studied. Three of the six nucleotide changes
were silent mutations. We speculate that they might be one of the
multiple changes contributing to the development of SCC in sun-
damaged skin. The role of the PTCH gene in the development of
SCC needs to be further explored.
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